Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial

This patient is expected to be the final patient in the second dosage cohort of the trial SAN JOSE, Calif., June 24, 2024 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks